Approximately 50% of melanomas at diagnosis harbour mutations in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene, a key serine-threonine kinase in the MAPK signalling pathway. This evidence concerns the gene BRAF and melanoma.